Why Order the Oncotype DX AR-V7 Nucleus Detect Test?
Quickly and confidently determine the best treatment option for your mCRPC patient.
Finding the most effective treatment for your patients with metastatic castration-resistant prostate cancer (mCRPC) can be a challenge. The Oncotype DX AR-V7 Nucleus Detect test helps you quickly and confidently determine next treatment.
The first and only test of its kind to identify patients who will NOT respond to AR-targeted therapies
Confidently guide next treatment decisions in mCRPC
Not all mCRPC patients respond to androgen receptor (AR)-targeted therapies, like abiraterone (Zytiga®) and enzalutamide (Xtandi®).1 When AR-targeted therapy fails, acquired resistance could be the cause.1 The only predictive and prognostic test for patients with mCRPC, the AR-V7 Nucleus Detect test:
- Accurately identifies patients who will not benefit from AR-targeted therapies.2-3
- Is predictive of improved overall survival with taxanes versus AR-targeted therapies.2-3
- Provides easy-to-interpret results (a positive or negative result).
The image above shows a possible mCRPC treatment path
The AR-V7 Nucleus Detect test provides unparalleled specificity by detecting AR-V7 proteins in the nucleus of circulating tumor cells (not cytoplasmic AR-V7 proteins). Find out more about nuclear detection.
Get fast results from a simple blood draw
The Oncotype DX AR-V7 Nucleus Detect test is a liquid biopsy assay that analyzes circulating tumor cells in a patient's blood. No intrusive or complicated procedures are required. The results are reported to the ordering physician through a secure portal, confirming the patient as either AR-V7+ or AR-V7-.
Optimizing Treatment Selection for mCRPC Using Oncotype DX AR-V7 Nucleus Detect Test
This webinar explains what metastatic castration-resistant prostate cancer (mCRPC) is and how it is currently treated. In addition it will explain the role of resistance to androgen receptor-targeted drugs like Xtandi and Zytiga and its impact on treating mCRPC.